Dr. Selvi C. Ersoy has been an Investigator at the Lundquist Institute (TLI) and an Assistant Adjunct Professor at the David Geffen School of Medicine at UCLA since 2024. Dr. Ersoy earned her Ph.D. from the University of California Santa Barbara in 2017 in the Department of Molecular, Cellular, and Developmental Biology in the laboratory of Dr. Michael Mahan. There, she studied the impacts of host-mimicking media on antimicrobial susceptibility profiles in various Gram-negative and Gram-Positive pathogens, including Salmonella, Escherichia coli, Streptococcus pneumonia, and methicillin-resistant Staphylococcus aureus (MRSA). In 2017, Dr. Ersoy joined the lab of Dr. Arnold Bayer at TLI for her post-doctoral training. Her research focused on the ability of HCO3, an abundant ion in mammalian tissues and blood, to stimulate MRSA sensitivity to β-lactam antibiotics both in vitro and in vivo. Dr. Ersoy has continued to investigate the scope, mechanisms, and translatability of this phenomenon in her current roles as Investigator and Faculty at TLI and the David Geffen School of Medicine. The primary goal of her research is to identify novel anti-MRSA therapeutic strategies for clinical practice.
Dr. Selvi C. Ersoy has been an Investigator at the Lundquist Institute (TLI) and an Assistant Adjunct Professor at the David Geffen School of Medicine at UCLA since 2024. Dr. Ersoy earned her Ph.D. from the University of California Santa Barbara in 2017 in the Department of Molecular, Cellular, and Developmental Biology in the laboratory of Dr. Michael Mahan. There, she studied the impacts of host-mimicking media on antimicrobial susceptibility profiles in various Gram-negative and Gram-Positive pathogens, including Salmonella, Escherichia coli, Streptococcus pneumonia, and methicillin-resistant Staphylococcus aureus (MRSA). In 2017, Dr. Ersoy joined the lab of Dr. Arnold Bayer at TLI for her post-doctoral training. Her research focused on the ability of HCO3, an abundant ion in mammalian tissues and blood, to stimulate MRSA sensitivity to β-lactam antibiotics both in vitro and in vivo. Dr. Ersoy has continued to investigate the scope, mechanisms, and translatability of this phenomenon in her current roles as Investigator and Faculty at TLI and the David Geffen School of Medicine. The primary goal of her research is to identify novel anti-MRSA therapeutic strategies for clinical practice.